M Untch Selected Research

Epirubicin (Ellence)

1/2021	Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
1/2017	Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
12/2014	Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
1/2014	Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
12/2013	Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
9/2011	PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
9/2011	PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
2/2011	Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.
9/2007	The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.
5/2007	Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

M Untch Research Topics

Disease

58	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2000
37	Neoplasms (Cancer) 01/2021 - 01/2000
8	Triple Negative Breast Neoplasms 07/2022 - 12/2013
7	Neoplasm Metastasis (Metastasis) 03/2016 - 01/2000
3	Thrombocytopenia (Thrombopenia) 01/2021 - 02/2011
2	Diarrhea 11/2016 - 02/2011
2	Disease Progression 04/2015 - 06/2001
2	Sarcoma (Soft Tissue Sarcoma) 02/2015 - 04/2006
2	Carcinoma (Carcinomatosis) 03/2014 - 06/2001
2	Residual Neoplasm 01/2010 - 06/2001
2	Cardiotoxicity 05/2004 - 09/2000
2	Ovarian Neoplasms (Ovarian Cancer) 06/2001 - 05/2000
1	Second Primary Neoplasms (Neoplasms, Second) 01/2022
1	Hemorrhage 01/2021
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2021
1	Pathologic Complete Response 01/2017
1	Dizziness (Lightheadedness) 11/2016
1	Febrile Neutropenia 11/2016
1	Myoma 02/2015
1	Leiomyoma (Uterine Fibroids) 02/2015
1	Airway Obstruction (Choking) 08/2013
1	Hiatal Hernia 08/2013
1	Inflammatory Breast Neoplasms 08/2012
1	Edema (Dropsy) 02/2011
1	Hypertension (High Blood Pressure) 02/2011
1	Hyperlipidemias (Hyperlipidemia) 02/2011
1	Leukopenia 02/2011
1	Mucositis 02/2011
1	Infections 02/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 02/2011
1	Brain Neoplasms (Brain Tumor) 04/2006

Drug/Important Bio-Agent (IBA)

19	Trastuzumab (Herceptin)FDA Link 01/2021 - 09/2000
17	Epirubicin (Ellence)FDA LinkGeneric 01/2021 - 01/2000
14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 05/2000
12	taxaneIBA 07/2022 - 09/2007
11	AnthracyclinesIBA 07/2022 - 12/2004
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 05/2000
7	Hormones (Hormone)IBA 01/2021 - 04/2002
6	Biomarkers (Surrogate Marker)IBA 07/2022 - 04/2002
6	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2013 - 01/2000
6	Plasminogen Activator Inhibitor 1IBA 05/2013 - 01/2000
5	Lapatinib (GW572016)FDA Link 01/2019 - 02/2011
5	AntibodiesIBA 09/2007 - 01/2001
4	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 05/2000
4	Proteins (Proteins, Gene)FDA Link 01/2015 - 09/2000
4	Docetaxel (Taxotere)FDA Link 12/2014 - 02/2011
4	Fluorouracil (Carac)FDA LinkGeneric 09/2007 - 09/2000
4	Plasminogen InactivatorsIBA 08/2001 - 01/2000
3	human ERBB2 proteinIBA 01/2021 - 06/2008
3	Bevacizumab (Avastin)FDA Link 12/2014 - 02/2011
3	Drug CombinationsIBA 09/2001 - 05/2000
3	Methotrexate (Mexate)FDA LinkGeneric 09/2001 - 09/2000
2	durvalumabIBA 07/2022 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2020 - 01/2019
2	ParaffinIBA 12/2018 - 01/2001
2	Zoledronic Acid (Zometa)FDA Link 03/2016 - 01/2016
2	Diphosphonates (Bisphosphonates)IBA 03/2016 - 01/2016
2	Everolimus FDA Link 12/2014 - 02/2011
2	Plasminogen Activators (Plasminogen Activator)IBA 05/2013 - 04/2006
2	Darbepoetin alfa (Aranesp)FDA Link 09/2011 - 09/2011
2	Vinorelbine (Navelbine)FDA LinkGeneric 10/2006 - 06/2001
2	Tissue ExtractsIBA 04/2006 - 08/2001
2	Adenosine Triphosphate (ATP)IBA 06/2001 - 05/2000
2	Pharmaceutical PreparationsIBA 06/2001 - 05/2000
1	veliparibIBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	PlatinumIBA 01/2021
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	olaparibIBA 01/2021
1	MutagensIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Formaldehyde (Formol)FDA Link 12/2018
1	Estrogen ReceptorsIBA 12/2018
1	130-nm albumin-bound paclitaxelIBA 01/2017
1	SolventsIBA 01/2017
1	pertuzumabIBA 01/2017
1	CreatinineIBA 11/2016
1	Clodronic Acid (Clodronate)IBA 03/2016
1	N,N'-bis(4-azidobenzoyl)cystineIBA 02/2016
1	HematinicsIBA 04/2015
1	Biosimilar PharmaceuticalsIBA 04/2015
1	Cysteine (L-Cysteine)FDA Link 01/2015
1	Capecitabine (Xeloda)FDA Link 01/2014
1	Messenger RNA (mRNA)IBA 03/2013
1	Growth Factor ReceptorsIBA 02/2011
1	bis(beta-carboxyethyl)tin dichlorideIBA 09/2007
1	Antineoplastic Agents (Antineoplastics)IBA 05/2007
1	A 7 (A-7)IBA 04/2006
1	SurvivinIBA 04/2006
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2006

Therapy/Procedure

35	Drug Therapy (Chemotherapy) 01/2021 - 01/2000
26	Therapeutics 01/2021 - 01/2000
19	Neoadjuvant Therapy 07/2022 - 06/2001
3	Adjuvant Chemotherapy 01/2019 - 01/2000
3	Hysterectomy 02/2015 - 04/2006
2	Cesarean Section (Caesarean Section) 03/2014 - 06/2004
1	Operative Surgical Procedures 02/2015
1	Morcellation 02/2015
1	Ex utero Intrapartum Treatment Procedures 08/2013
1	Curettage 04/2006